Our portfolio

Built on the principles of speed, scale and equitable access, CEPI is supporting the research and development of a diverse portfolio of vaccine candidates based on a range of vaccine approaches. Including Bio E, CEPI has invested in 12 vaccine candidates, ten of which are still in development.

In addition to COVID-19, CEPI's priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine development against unknown pathogens (Disease X).

Filter by:

PRODUCT DEVELOPERS

All
Auro Vaccines & PATH
Biological E Limited
Clover Biopharmaceuticals
Colorado State University
CureVac
Emergent Biosolutions & PATH
IDT Biologika
Imperial College London
Inovio Pharmaceuticals
Institut Pasteur, Themis Bioscience, University of Pittsburgh
International AIDS Vaccine Initiative
International Vaccine Institute and Bharat Biotech
Janssen Vaccines & University of Oxford
Moderna, Inc.
Novavax, Inc.
Public Health Vaccines
SK bioscience
Themis Bioscience
University of Hong Kong
University of Oxford and Astrazeneca
University of Queensland
University of Tokyo
Valneva SE
VBI Vaccines
Wageningen Bioveterinary Research

DISEASE

All
Chikungunya
COVID-19
Lassa virus
Marburg virus
MERS coronavirus
Nipah virus
Rift Valley Fever

VACCINE TYPE

All
ChAdOx1
Enveloped virus like particle (eVLP)
HeV-sG-V vaccine
Inactivated Whole Virion vaccine
Live attenuated vaccine
Measles vector
Nucleic acid
Protein Antigen
Recombinant protein
Recombinant protein nanoparticle technology
Recombinant viral vector
S-Trimer vaccine

PHASE

All
Development Discontinued
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase III - Authorised for use in multiple countries
Phase III - WHO EUL granted
Preclinical

Filter by product developers:

All
Auro Vaccines & PATH
Biological E Limited
Clover Biopharmaceuticals
Colorado State University
CureVac
Emergent Biosolutions & PATH
IDT Biologika
Imperial College London
Inovio Pharmaceuticals
Institut Pasteur, Themis Bioscience, University of Pittsburgh
International AIDS Vaccine Initiative
International Vaccine Institute and Bharat Biotech
Janssen Vaccines & University of Oxford
Moderna, Inc.
Novavax, Inc.
Public Health Vaccines
SK bioscience
Themis Bioscience
University of Hong Kong
University of Oxford and Astrazeneca
University of Queensland
University of Tokyo
Valneva SE
VBI Vaccines
Wageningen Bioveterinary Research

Filter by disease:

All
Chikungunya
COVID-19
Lassa virus
Marburg virus
MERS coronavirus
Nipah virus
Rift Valley Fever

Filter by vaccine type:

All
ChAdOx1
Enveloped virus like particle (eVLP)
HeV-sG-V vaccine
Inactivated Whole Virion vaccine
Live attenuated vaccine
Measles vector
Nucleic acid
Protein Antigen
Recombinant protein
Recombinant protein nanoparticle technology
Recombinant viral vector
S-Trimer vaccine

Filter by phase:

All
Development Discontinued
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase III - Authorised for use in multiple countries
Phase III - WHO EUL granted
Preclinical

N/A

No result